Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Chief Business Officer | February 26, 2026 | March 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.64 · Expires 2036-02-26 | Direct | 95,000 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 95,000 · Balance 95,000 F1: The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Mar 2, 2026 16:22 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $17.64 | $0.00 |
DisclosureSEC source: 0002090172-26-000002 · form4-03022026_090334.xml · derivative · entry 1 Boyd Taylor · CIK 0002090172 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| October 01, 2025 Filed Oct 6, 2025 16:28 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0002090172-25-000002 · primary_doc.xml · derivative · entry 1 Boyd Taylor · CIK 0002090172 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2035-10-01 F1 · derivative.exercise_date: The stock option was granted on October 1, 2025, and vests over four years, with the first 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, subject to the reporting person's continued employment with the Company on each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.